Analyst Overvalued Stocks on the ASE April 2024

April 30, 2024

Analyst Overvalued

Companies on this list are considered overvalued based on the analyst consensus. This means that the average analyst target price is less than the close price.

American Stock Exchange

NYSE American, formerly known as the American Stock Exchange (ASE), and more recently as NYSE MKT, is an American stock exchange located in New York City.

About the Data

This table includes the close price and analyst target price mean from most recent available data. The fiscal year indicates the year for the analyst target price, as the target may not always be for the current year. The number of estimates indicates the number of analyst targets used to calculate the target price mean.

How do you use this table?

Analysts believe that the companies on this list will see the close price drop to their target price mean by the target year indicated. Companies with a large analyst following or large difference between close price and target price are particularly interesting to investigate further. This becomes a starting point for further analysis to understand why these companies are overvalued. Stocks in this category are generally sold to preserve capital.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose PriceTarget Price MeanTarget YearNumber of EstimatesCurrency
CATX Perspective Therapeutics Inc 1.64 1.50 2025 1 USD
LSF Laird Superfood Inc 2.01 1.90 2024 2 USD
All data provided as at market close April 28, 2024.

Company Details

Perspective Therapeutics Inc

CATX:ASE

Close Price

1.64

Target Price Mean

1.50

Target Year

2025

Target Price # Estimates

1

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Access the stockcalc valuation


Laird Superfood Inc

LSF:ASE

Close Price

2.01

Target Price Mean

1.90

Target Year

2024

Target Price # Estimates

2

Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.

Access the stockcalc valuation


Perspective Therapeutics and Laird Superfood are among the most overvalued ASE stocks this month. See the most overvalued companies on the blog: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-ase-april-2024
Perspective Therapeutics $CATX and Laird Superfood $LSF on the #ASE among the most overvalued this month. See the full list of overvalued companies: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-ase-april-2024
Perspective Therapeutics and Laird Superfood are among the most overvalued ASE stocks this month. See the most overvalued companies on the blog: https://www.stockcalc.com/Blog/analyst-overvalued-stocks-ase-april-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.